: Preliminary results of a study conducted by the Pontifical Catholic University in Chile showed that the COVID-19 Sinovac vaccine booster dose could activate cellular immunity against the Omicron variant, on subjects who were given two doses of the same vaccine previously.
Dr Alexis, in a statement released by Pharmaniaga today, said those who have received the COVID-19 Sinovac vaccine booster dose had T cell levels that are activated against the Omicron variant in a similar way to the original strain. Meanwhile, UC’s Academic and Scientific director for the CoronaVac Scientific-Clinical Study in Chile, Dr Susan Bueno said, it was most likely that partial recognition of these variants had contributed to the effectiveness of the vaccine among the population, despite the variants being widespread in Chile.
The statement also informed that researchers in Chile in collaboration with the Catholic University, the University of Chile, the La Jolla Institute for Immunology in California and Sinovac in China were also in the midst of conducting a study on the antibody response against the new variant.